AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge
AstraZeneca is investing $50 billion in the United States by 2030 to expand medicines manufacturing and R&D, targeting chronic diseases, including rare conditions1.
A central part of this investment includes a multi-billion dollar drug substance manufacturing center in Virginia, which will be AstraZeneca’s largest global facility1.
The company is onshoring its rare disease portfolio to the US, notably with a $2 billion expansion in Maryland aimed at biologics and rare diseases—adding 300 highly skilled jobs36.
These manufacturing complexes will utilize artificial intelligence (AI), automation, and data analytics to enhance production and are expected to be operational by 202915.
Additional investments expand R&D facilities in Gaithersburg, Maryland and Kendall Square, Cambridge, Massachusetts, as well as manufacturing sites in Indiana, Texas, California, and Maryland1.
The strategic goal is to reach $80 billion in total revenue by 2030, with half generated in the US1.
AstraZeneca’s rare disease unit also recently acquired Pfizer’s pre-clinical gene therapy portfolio for $1 billion, reflecting aggressive pipeline growth in rare diseases42.
US Secretary of Commerce Howard Lutnick praised AstraZeneca’s decision as supporting domestic pharma supply resiliency while strengthening US leadership in drug innovation and manufacturing1.
Sources:
1. https://www.biospace.com/press-releases/astrazeneca-plans-to-invest-50-billion-in-america-for-medicines-manufacturing-and-r-d
2. https://accesstomedicinefoundation.org/company/astrazeneca-plc
3. https://www.europeanpharmaceuticalreview.com/news/268133/astrazeneca-us-manufacturing-2-billion-maryland-investment/
4. https://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/AstraZeneca-s-Rare-Disease-Unit-Buy-Pfizer-Portfolio-for-1-Billion-44882478/
5. https://www.nasdaq.com/articles/why-astrazeneca-stock-bumped-higher-today